RxDoctor Payments Data

Kellee English, PA

Physician Assistant · Phoenix, AZNPI 1164985644

Payments from drug & device makers

$8,375in general payments, 2019–2025

Across 421 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Incyte Corporation$792
  • Dermavant Sciences, Inc.$714
  • AbbVie$694
  • Regeneron Healthcare Solutions, Inc.$625
  • Sanofi$600
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$8,22098%
  • Education$1552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,375 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$135,686
Medicare patients
603
Services billed
2,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$65,071
Dupixent PenDupilumab12$46,528
Clobetasol Propionate123$4,313
Fluorouracil37$2,628
Ketoconazole149$2,204
Tacrolimus11$1,425
Doxycycline Hyclate54$1,386
Metronidazole23$1,282
Triamcinolone Acetonide119$1,230
Fluocinolone Acetonide18$1,003
Clindamycin Phosphate26$715
Imiquimod11$548
Hydrocortisone111$496
CiclopiroxCiclopirox Olamine11$335
Mupirocin40$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$130$65,07113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →